This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: K50.1 | Special Copayment Reduction: V130 |
| B. Synonyms | — |
| C. Adult onset | Likelihood of first presentation in adulthood high — Crohn disease peaks in onset at 15–35 years of age, and first diagnosis is most common in adults. The colonic type features prominent bloody stools and tenesmus, and differentiation from ulcerative colitis is important. |
| 1. History | First described by Crohn, Ginzburg and Oppenheimer in 1932 → steroid and sulfasalazine treatment in the 1960s → FDA approval of infliximab in 1998 → discovery of the NOD2 gene in 2001 → introduction of various biologics in 2014–2022. |
| 2. Causes | Genetic predisposition (NOD2, ATG16L1, IL-23R, etc.) + gut microbial abnormalities + abnormal immune response. Smoking, Westernized diet and antibiotic use are risk factors. Damage to the mucosal defense barrier is the starting point. |
| 3. Genetics | Multifactorial inheritance. NOD2 variants (25–30% of Western patients). More than 200 loci associated, including IL-23R, ATG16L1 and TNFSF15. Monozygotic twin concordance 37–58%. Risk in first-degree relatives increased about 10–15-fold. |
| 4. General epidemiology | Western prevalence 300/100,000. Korea 40–60/100,000 (rapidly increasing). Main peak age of onset 15–35 years. Similar in men and women. Special Copayment Reduction V130. Combined small and large bowel involvement common in Korea. |
| 5. Pathophysiology | Mucosal barrier damage → innate immunity (NOD2 and PRR activation) → Th1 and Th17 hyperactivation → secretion of TNF-α, IL-12 and IL-23 → formation of non-caseating granulomas → transmural inflammation → strictures, fistulas, abscesses. |
| 6. Symptoms | Abdominal pain, diarrhea, fever, weight loss, perianal lesions (fistulas, abscesses). In the colonic type, bloody stools, tenesmus and perianal complications are more frequent. Extraintestinal symptoms (arthritis, uveitis, erythema nodosum). |
| 7. Signs | Abdominal tenderness and mass, elevated CRP and ESR, anemia. Endoscopy: segmental aphthous ulcers, cobblestone mucosa. MRE: bowel wall thickening, strictures, fistulas. |
| 8. Screening | No population screening. Fecal calprotectin + colonoscopy for chronic abdominal pain, diarrhea and bloody stools. Early testing if there is a family history. Differentiation from intestinal tuberculosis is important in Korea. |
| 9. Diagnosis | Colonoscopy with ileal intubation, biopsy (non-caseating granulomas), MR enterography. Active exclusion of intestinal tuberculosis (IGRA, AFB culture, chest CT). Integrated clinical, endoscopic, imaging and pathologic diagnosis. |
| 10. Treatment | Steroids (induction of remission), azathioprine (maintenance), anti-TNF (infliximab, adalimumab), vedolizumab, ustekinumab. Fistulas: anti-TNF + surgery. Treat-to-target: mucosal healing as the goal. |
| 11. Prognosis | About 30–50% require surgery within 10 years. Surgery rates decreased after the introduction of biologics. Life expectancy nearly normal. Regular surveillance needed because of increased risk of colorectal and small bowel cancer. |
| 12. Prevention | Smoking cessation (most important). Early biologic treatment. Keep vaccinations up to date. Regular endoscopic surveillance. Patient education and self-management. |
| 13. References | Torres J et al. Crohn's disease. Lancet. 2017 … and 9 other references |
Crohn's disease was first described as an independent disease entity in 1932 in the paper "Regional ileitis: A pathological and clinical entity" published jointly in JAMA by the American gastroenterologists Burrill B. Crohn, Leon Ginzburg and Gordon D. Oppenheimer. Reporting 14 cases with segmental inflammation of the terminal ileum, submucosal fibrosis and granuloma formation, they named the disease 'regional ileitis'. At the time it was regarded as a disease confined to the small intestine, but it was later shown to occur throughout the gastrointestinal tract, including the colon, upper gastrointestinal tract and perianal region.
In the 1950s–1960s, as it became clear that Crohn's disease and ulcerative colitis (UC) are separate diseases, the concept of 'inflammatory bowel disease (IBD)' encompassing both became established. In the 1960s, steroids and sulfasalazine were the main treatments. Treatment options expanded with the introduction of azathioprine in 1975 and 5-aminosalicylate preparations in 1984.
In 1998, the anti-TNF-α agent infliximab was first approved for Crohn's disease, opening a new era of biologic therapy. Subsequently, various biologics were approved, including adalimumab (2006), certolizumab pegol (2008), ustekinumab (2016) and vedolizumab (2014). In 2012, a 'treat-to-target' paradigm was proposed with mucosal healing as the treatment goal in Crohn's disease.
In genetics, the first Crohn's disease susceptibility gene, NOD2/CARD15, was identified in 2001, and large-scale genome-wide association studies (GWAS) subsequently identified more than 200 IBD-associated loci. In Korea, case reports of Crohn's disease began in the 1960s, and a sharp increase in incidence has been reported since the 1990s, drawing attention to its association with Westernized lifestyles. Since the 2000s, expanded National Health Insurance coverage of biologics has greatly improved access to treatment in Korea.
The cause of Crohn's disease has not been fully elucidated; current understanding is represented by a 'multifactorial interaction model' in which an abnormal immune response to gut microbial antigens in genetically predisposed individuals causes chronic inflammation.
Genetic factors: the best-known susceptibility gene is NOD2/CARD15, variants of which are found in about 25–30% of Western patients with Crohn's disease. NOD2 is an intracellular receptor that recognizes muramyl dipeptide, a component of the bacterial cell wall; when it is mutated, bacterial sensing and defense responses are impaired. In addition, more than 200 loci, including ATG16L1 (autophagy regulation), IRGM (autophagy), IL-23R (IL-23 signaling), LRRK2 and FUT2, are associated with increased IBD risk.
Gut microbiota (microbiome): in patients with Crohn's disease, reduced diversity of gut bacteria (dysbiosis) and changes in specific pathogenic bacteria (e.g., mucosa-adherent Escherichia coli, decreased Faecalibacterium prausnitzii) are observed. Damage to the intestinal mucosal defense barrier and bacterial invasion are proposed as the initial stage of abnormal immune activation.
Immune dysregulation: the normal intestinal immune system maintains tolerance toward commensal bacteria, but in Crohn's disease Th1 and Th17 immune responses are hyperactivated, with excessive secretion of proinflammatory cytokines such as TNF-α, IFN-γ, IL-12, IL-23 and IL-17. Regulatory T cell (Treg) function is also impaired, so immune tolerance is not maintained.
Environmental factors: Westernized diet (high-fat, low-fiber diet), antibiotic use, smoking (a risk factor that worsens Crohn's disease), use of nonsteroidal anti-inflammatory drugs (NSAIDs) and reduced exposure to infections in childhood (hygiene hypothesis) are studied as environmental factors that affect the risk of developing Crohn's disease. Smoking increases the risk of Crohn's disease about 2-fold and raises the risk of surgery, so smoking cessation is strongly recommended.
Crohn's disease has a complex polygenic genetic architecture, and by 2024 more than 240 IBD-associated loci had been identified through GWAS. Some of these loci are shared between Crohn's disease and UC, and some are specific to Crohn's disease.
The NOD2/CARD15 gene is located on the long arm of chromosome 16 (16q12.1) and is the largest single risk gene in Crohn's disease in Western populations. Three NOD2 variants, p.Arg702Trp (R702W), p.Gly908Arg (G908R) and p.Leu1007Profs*2 (1007fs), are most strongly associated with Crohn's disease risk. A risk increase of about 2–3-fold in heterozygotes and about 20–40-fold in homozygotes or compound heterozygotes is reported. However, the frequency of NOD2 variants in East Asian patients with Crohn's disease, including Koreans, is markedly lower than in Western patients, suggesting that the genetic basis of Crohn's disease in East Asia differs from that in the West.
ATG16L1 (Autophagy-related 16-like 1) and IRGM (Immunity-related GTPase M): genes involved in the autophagy pathway that affect the ability to handle intracellular bacteria. The ATG16L1 T300A variant is commonly found in Western Crohn's disease.
IL-23R: the IL-23 receptor gene, involved in regulation of the IL-23–Th17 axis. Individuals carrying the protective IL-23R variant (R381Q) have a reduced risk of Crohn's disease. Conversely, IL-23R gain-of-function variants increase risk. This pathway is the therapeutic target of biologics such as ustekinumab (anti-IL-12/23p40).
The monozygotic twin concordance rate in Crohn's disease is about 37–58%, suggesting that the genetic contribution is large but environmental factors are also essential. The risk of IBD in first-degree relatives is about 10–15 times that of the general population. Studies show that in Korean patients with Crohn's disease, TNFSF15 (the TL1A gene, IBD5 locus) has a stronger association than in Western patients, confirming the existence of ethnic genetic differences.
Crohn's disease occurs worldwide but has the highest prevalence and incidence in Western Europe and North America. In Northern Europe, prevalence is about 300–320 per 100,000 population and incidence about 6–15/100,000/year. Incidence is lower in Asia and South America but has been increasing sharply over the past several decades.
Age and sex distribution: the age-of-onset distribution of Crohn's disease tends to be bimodal, with a first peak at 15–35 years and a smaller second peak at 50–70 years. The sex ratio is generally similar, but there are reports of slightly more frequent onset in women in Western countries. Pediatric onset (before age 18) accounts for about 25–30%.
Epidemiology in Korea: in Korea, the incidence of Crohn's disease has risen sharply since the 1990s, and its prevalence in the 2020s is about 40–60/100,000, lower than in Western countries but high for Asia. Features of Crohn's disease in Korea are frequent isolated small bowel involvement or combined small and large bowel involvement and a high frequency of perianal lesions. Studies based on Korean National Health Insurance data report a pattern of frequent occurrence in young adult men (around their 20s). Crohn's disease is eligible for rare disease Special Copayment Reduction (V130) registration, and after registration a reduced copayment benefit is provided.
Rising incidence: in regions where IBD was previously rare, such as Asia, South America and Africa, incidence is rising with the adoption of Westernized lifestyles. This is understood to result from a combined contribution of dietary changes (Western high-fat, low-fiber diet), increased antibiotic use, changes in the microbiome with improved hygiene (hygiene hypothesis), environmental pollution and other factors.
The pathophysiology of Crohn's disease is understood as uncontrolled chronic intestinal inflammation triggered by gut microbes and environmental factors in genetically susceptible individuals. This process broadly consists of damage to the mucosal defense barrier, innate immune activation, a hyperactivated adaptive immune response, and tissue damage and fibrosis.
Damage to the mucosal defense barrier: in Crohn's disease, barrier function is impaired by abnormal tight junctions between intestinal epithelial cells, a reduced mucus layer and decreased secretion of antimicrobial peptides (defensins). As a result, bacteria and bacterial products in the intestinal lumen penetrate into the submucosa and activate immune responses.
Innate immunity and the NOD2 pathway: pattern recognition receptors (PRR) on dendritic cells and macrophages recognize bacterial components (PAMP), activate the NF-κB pathway and secrete proinflammatory cytokines (TNF-α, IL-1β, IL-6, IL-12, IL-23). In individuals with NOD2 loss-of-function variants, bacterial sensing and defense responses are insufficient, accelerating bacterial invasion.
Adaptive immune response: the Th1 and Th17 axes: IL-12 drives differentiation of naive T cells into Th1 cells (producing IFN-γ), and IL-23 into Th17 cells (producing IL-17A and IL-22). In Crohn's disease, Th1 and Th17 immune responses are hyperactivated, maintaining a persistent proinflammatory environment. Immune tolerance fails because of impaired regulatory T cell (Treg) function.
Granuloma formation: the non-caseating granuloma, a characteristic histologic finding of Crohn's disease, is formed by aggregation of macrophages, epithelioid cells, multinucleated giant cells and lymphocytes. Granulomas are a manifestation of the chronic immune response to bacterial or foreign antigens and form nodes within the tissue, causing damage to surrounding tissue.
Fibrosis and stricture formation: chronic recurrent inflammation causes fibroblast activation and excessive deposition of extracellular matrix, leading to bowel wall thickening, strictures and obstruction. Strictures are inflammatory (reversible) at first but become fibrotic (irreversible) with progression. Fistulas and abscesses form when transmural inflammation penetrates into adjacent structures.
The clinical symptoms of Crohn's disease vary greatly depending on the site of involvement, the disease phenotype (inflammatory, stricturing, penetrating) and disease activity. Symptoms may progress gradually or worsen suddenly, and intestinal and extraintestinal symptoms may appear together.
Abdominal pain is the most common symptom of Crohn's disease. It is characterized by crampy pain in the lower abdomen or around the umbilicus that worsens after meals or with defecation. With small bowel strictures, postprandial pain and abdominal distension become severe, and progression to bowel obstruction causes severe abdominal pain and vomiting.
Diarrhea is the second most common symptom, characterized by loose, frequent stools. Small bowel involvement may be accompanied by large-volume watery diarrhea, and colonic involvement by mucus and bloody stools. When the rectum is not involved, tenesmus is less common than in UC.
Systemic symptoms: fever, fatigue, weight loss and loss of appetite are common. Particularly in pediatric and adolescent patients, growth retardation and delayed puberty are important systemic symptoms. Nutritional deficiencies (vitamin B12, folate, iron, vitamin D, zinc, etc.) commonly accompany the disease.
Perianal lesions: perianal fistulas, abscesses and fissures accompany about 30–40% of Korean patients with Crohn's disease. Perianal lesions cause pain, discharge and discomfort with defecation and, when difficult to treat, greatly reduce quality of life.
Extraintestinal symptoms: extraintestinal symptoms may occur in the mouth (aphthous stomatitis), skin (erythema nodosum, pyoderma gangrenosum), eyes (uveitis, scleritis), joints (peripheral arthritis, ankylosing spondylitis) and hepatobiliary system (primary sclerosing cholangitis). Extraintestinal symptoms are divided into those linked to intestinal disease activity and those that occur independently.
The physical signs of Crohn's disease vary depending on the site of involvement and the presence of complications.
Abdominal physical findings: tenderness over the affected bowel is most common. With severe small bowel involvement, tenderness and a soft tissue mass (phlegmon) may be palpable in the right lower quadrant. Signs of peritoneal irritation (rebound tenderness, guarding) suggest bowel perforation or abscess formation. Abdominal distension and changes in bowel sounds (hyperactive or absent) suggest possible bowel obstruction.
Perianal findings: anal skin tags, external fistula openings, abscesses and fissures may be observed. For accurate assessment of perianal lesions, pelvic MRI and exam under anesthesia (EUA) are standard.
Growth retardation (children and adolescents): in pediatric patients with Crohn's disease, reduced growth velocity, height and weight below standard and delayed bone age are confirmed as physical findings. Nutritional deficiency and growth hormone resistance due to chronic inflammation are proposed as mechanisms.
Laboratory findings: elevated C-reactive protein (CRP), elevated erythrocyte sedimentation rate (ESR), leukocytosis, hypoalbuminemia, anemia (iron deficiency or anemia of chronic disease) and low vitamin B12 and D are commonly observed. Fecal calprotectin (FC) is a noninvasive biomarker of intestinal inflammation, used to assess Crohn's disease activity and monitor treatment response.
Endoscopic and imaging findings: on colonoscopy, segmental discontinuous inflammation, aphthous ulcers, transverse fissuring ulcers and cobblestone appearance of the mucosa are characteristic. Small bowel follow-through, MR enterography (MRE) and CT enterography (CTE) confirm mucosal thickening, strictures, fistulas and abscesses.
There is no general population screening program for Crohn's disease. However, symptom-based early diagnosis and follow-up of high-risk groups are important.
Symptom-based early referral: patients with chronic abdominal pain, diarrhea, bloody stools, weight loss or perianal lesions (fistulas, abscesses) persisting for 3 months or more need referral to gastroenterology to differentiate IBD, including Crohn's disease. If gastrointestinal symptoms persist with fever, infectious enteritis, tuberculosis and the like must be differentiated at the same time.
With a family history: when a first-degree relative has IBD, IBD risk increases 10–15-fold, so if gastrointestinal symptoms occur, active testing is performed early. Screening asymptomatic individuals on the basis of family history alone is currently not recommended.
Fecal calprotectin: a noninvasive IBD screening tool useful for differentiation from functional bowel disorders such as irritable bowel syndrome (IBS). FC ≥50 μg/g suggests organic bowel disease, and endoscopy is recommended. It is especially useful for IBD screening in children.
Serum ASCA (anti-Saccharomyces cerevisiae antibodies): an antibody relatively specific for Crohn's disease, used as an adjunct in differentiating IBD, but its sensitivity and specificity are limited as a stand-alone diagnostic tool.
Diagnosis of Crohn's disease is made through a multidisciplinary approach integrating clinical findings, endoscopic findings, imaging findings, tissue biopsy and biochemical tests. No single test confirms the diagnosis, and differentiation from infectious enteritis, intestinal tuberculosis, Behçet disease, ulcerative colitis and others is essential.
Colonoscopy with ileal intubation: the most important diagnostic tool, providing mucosal findings (aphthous ulcers, linear ulcers, cobblestone mucosa, segmental lesions, rectal sparing) and tissue biopsy. Tissue is sampled from multiple sites to evaluate non-caseating granulomas, focal active colitis and dysplasia.
Small bowel imaging (MR enterography, CT enterography): essential for evaluating small bowel lesions not accessible by colonoscopy. It evaluates mucosal thickening, strictures, fistulas, abscesses and mesenteric fat wrapping. When intra-abdominal abscess or obstruction is suspected, abdominal CT is performed first. MRI is superior for evaluating penetrating lesions such as fistulas and abscesses without radiation exposure.
Upper gastrointestinal endoscopy: evaluates involvement of the upper gastrointestinal tract (esophagus, stomach, duodenum). Gastric and duodenal involvement is found in about 10–15% of patients with Crohn's disease.
Differentiation from intestinal tuberculosis: in Korea, intestinal tuberculosis is an important differential diagnosis. Active exclusion testing is needed, including the tuberculin skin test (TST), interferon-γ release assay (IGRA), chest CT, AFB smear and culture, and PCR. Biologics should be started after tuberculosis and active infection have been excluded.
Histologic confirmation: the presence of non-caseating granulomas strongly supports a diagnosis of Crohn's disease, but granulomas are not observed in every Crohn's disease biopsy (found in only about 30–60%). Ideally, the granuloma is located in the submucosa or deeper.
The treatment goals of Crohn's disease are mucosal healing, maintenance of clinical remission, prevention of long-term complications (strictures, fistulas, surgery) and improved quality of life. The 'treat-to-target' strategy (target indicators: clinical, endoscopic and biomarker) is the standard of modern treatment.
5-aminosalicylic acid (5-ASA, mesalamine): used to a limited extent in mild colonic Crohn's disease, but its effect in small bowel Crohn's disease is insufficient, and many guidelines currently do not recommend it as first-line treatment.
Steroids (prednisone, budesonide): used to induce remission in moderate to severe active Crohn's disease. When disease is confined to the ileum and right colon, budesonide has fewer systemic adverse effects. Steroids should not be used long-term to maintain remission, and if dependence develops, treatment is switched to steroid-sparing therapy.
Immunomodulators (azathioprine, 6-MP, methotrexate): used for maintenance of remission and steroid-dependent Crohn's disease. For azathioprine and 6-MP, the dose is determined after testing TPMT enzyme activity. Methotrexate is an alternative for patients intolerant of or unresponsive to azathioprine.
Biologics — anti-TNF-α: infliximab (intravenous), adalimumab (subcutaneous) and certolizumab pegol are used. Indications are moderate to severe Crohn's disease, fistulizing Crohn's disease, and steroid dependence or resistance. Tuberculosis, hepatitis B and infection must be screened for before treatment.
Biologics — anti-integrin and anti-IL-12/23: vedolizumab (anti-α4β7 integrin) acts gut-selectively and has fewer systemic immunosuppressive adverse effects. Ustekinumab (anti-IL-12/23p40) is effective in patients who have failed TNF therapy and is given subcutaneously or intravenously.
Small-molecule drugs: risankizumab (anti-IL-23p19, FDA approved 2022) and JAK inhibitors (upadacitinib, FDA approved 2023) provide additional options for moderate to severe Crohn's disease.
Surgery: surgery (strictureplasty, bowel resection, fistulectomy, etc.) is needed for bowel perforation, obstruction, massive bleeding, severe drug-refractory disease and fistula or abscess complications. Drug therapy (immunomodulators, biologics) to prevent postoperative recurrence is recommended.
Crohn's disease has a chronic relapsing course, and even with appropriate treatment the risk of disease progression and complications persists over the long term. However, since the introduction of biologics, the prognosis has improved overall.
Disease progression: stricturing or penetrating complications develop in about 50% of patients within 5 years of diagnosis, and about 30–50% of patients undergo surgery within 10 years. Early aggressive treatment (top-down strategy, early use of biologics) is effective in reducing complications and surgery rates.
Postoperative recurrence: the clinical recurrence rate after surgery is about 25–30% within 5 years, and maintenance therapy with immunomodulators or biologics after surgery can lower the recurrence rate. Postoperative endoscopic follow-up (Rutgeerts score) objectively assesses recurrence at the surgical site.
Quality of life and social functioning: patients with Crohn's disease have high psychiatric comorbidity such as anxiety and depression, and reduced occupational functioning, disrupted schooling and limited social activities are common. Active symptom management, mental health support and patient education are important for improving quality of life.
Cancer risk: in Crohn's disease with small bowel involvement, the risk of small bowel cancer (adenocarcinoma, lymphoma) increases. In Crohn's disease with colonic involvement, the risk of colorectal cancer is about 2–3 times higher than in the general population, and the extent of involvement and disease duration are risk factors. Regular endoscopic surveillance is recommended for patients with colonic Crohn's disease.
Life expectancy: with current levels of treatment, the life expectancy of patients with Crohn's disease is almost the same as that of the general population. The main causes of death are infections (especially in patients on immunosuppressants), surgical complications, cancer and cardiovascular disease.
There is no established method to prevent the occurrence of Crohn's disease itself. However, risk factor control and strategies to prevent complications after diagnosis are important.
Smoking cessation: smoking increases the risk of Crohn's disease about 2-fold and raises the risk of relapse and surgery in affected patients. Smoking cessation is effective both for preventing Crohn's disease and for improving the prognosis of affected patients and is strongly recommended for all patients with Crohn's disease.
Early use of biologics (early top-down strategy): in patients with poor prognostic factors (extensive small bowel involvement, perianal lesions, steroid dependence at diagnosis, children with growth retardation, etc.), early use of biologics is effective in preventing disease progression and surgery.
Infection prevention: because the risk of infection increases during treatment with immunosuppressants and biologics, vaccinations against influenza, pneumococcus, hepatitis B, varicella and herpes zoster (recombinant zoster vaccine) are kept up to date. Live vaccines are avoided during immunosuppressive treatment.
Regular follow-up: in patients with Crohn's disease involving the colon, endoscopic surveillance according to disease duration detects colorectal cancer early. Small bowel imaging follow-up detects asymptomatic strictures and penetrating lesions early. Bone density testing (in patients using steroids) and vitamin and mineral supplementation prevent osteoporosis and nutritional deficiencies.
Patient education and self-management: for preventing complications, it is important that patients with Crohn's disease understand the disease well and have the self-management ability to recognize worsening symptoms early and contact their medical team promptly. Participation in IBD patient support groups and education by specialist nurses are helpful.
Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389(10080):1741-1755. DOI: 10.1016/S0140-6736(16)31711-1. PMID: 27914655.
Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504-1517. DOI: 10.1053/j.gastro.2004.01.063. PMID: 15168363.
Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769-2778. DOI: 10.1016/S0140-6736(17)32448-0. PMID: 29050646.
Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380(9853):1590-1605. DOI: 10.1016/S0140-6736(12)60026-9. PMID: 22914295.
Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology. 2011;140(6):1704-1712. DOI: 10.1053/j.gastro.2011.01.051. PMID: 21530736.
Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver. 2010;4(1):1-14. DOI: 10.5009/gnl.2010.4.1.1. PMID: 20479907.
Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severely active luminal and fistulizing Crohn's disease. Gastroenterology. 2021;160(7):2496-2508. DOI: 10.1053/j.gastro.2021.04.048. PMID: 33940120.
Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324-1338. DOI: 10.1038/ajg.2015.233. PMID: 26303131.
Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease (SONIC). N Engl J Med. 2010;362(15):1383-1395. DOI: 10.1056/NEJMoa0904492. PMID: 20393175.
Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005. Inflamm Bowel Dis. 2008;14(4):542-549. DOI: 10.1002/ibd.20310. PMID: 17941073.